VivoSeq
Gastroenterology

Gastroesophageal Reflux

0

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Gastroesophageal Reflux is an early-stage landscape with 0 programs across 6 companies. The most active players are Johnson & Johnson, Addex Pharma S.A., Novartis.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalA

Addex Pharma S.A.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalI

Ironwood Pharmaceuticals, Inc.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed8 · 47%
Terminated4 · 24%
Unknown status2 · 12%
Recruiting1 · 6%
Active, not recruiting1 · 6%
Enrolling by invitation1 · 6%

Clinical Trials

Trial Activity

17 trials

A Non-Interventional Study to Investigate the Effectiveness of Hydrotalcite to Relieve Acid-Related Symptoms Due to an Acid Rebound After Discontinuation of a Non/No Longer Indicated Long-Term PPI Therapy.
Recruiting·Bayer logoBayer·N/A·NCT07291700·167 enrolled
Research to Further Inform Thinking About the Role of LINX for Reflux Disease
Active, not recruiting·—·N/A·NCT04253392·500 enrolled
Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device
Enrolling by invitation·VVanderbilt University Medical Center·N/A·NCT03103789·75 enrolled
Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux
Completed·Novartis logoNovartis·Phase 1·NCT00414856·34 enrolled
Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT01018160·1,197 enrolled
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Completed·AAddex Pharma S.A.·Phase 2·NCT00820079·120 enrolled
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
Completed·AAddex Pharma S.A.·Phase 2·NCT00810485·298 enrolled
Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
Completed·IIronwood Pharmaceuticals, Inc.·Phase 2·NCT02030925·93 enrolled
The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux
Completed·Takeda logoTakeda·Phase 3·NCT00324974·162 enrolled
Methoclopramide for Gastroesophageal Reflux in Premature Infants
Completed·—·Phase 4·NCT02907632·490 enrolled
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
Completed·SSeoul National University Hospital·Phase 1/2·NCT01946971·12 enrolled
Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion
Terminated·PProfil Institut für Stoffwechselforschung GmbH·Phase 1·NCT02231658·109 enrolled
Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol
Terminated·Johnson & Johnson logoJohnson & Johnson·N/A·NCT00511966·1,049 enrolled
Fexofenadine Use in Gastroesophageal Reflux Symptoms
Terminated·SStanford University·Phase 2·NCT03425097·11 enrolled
Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux
Terminated·AAmerican Institute for Voice and Ear Research·Phase 4·NCT00369265·18 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)